【摘要】 目的探讨孟鲁司特钠辅助阿奇霉素治疗小儿喘息性支气管炎的效果。方法选取2016年1月~2017年10月于我院就诊的120例患有喘息性支气管炎的患儿作为研究对象,依照随机数字表法将其分为单独用药组和联合用药组,每组各60例。单独用药组患儿给予阿奇霉素治疗,联合用药组患儿予以孟鲁司特钠联合阿奇霉素进行治疗。比较分析两组患儿用药后的治疗效果、症状改善时间、超敏C反应蛋白指标和不良反应发生率。结果治疗后,联合用药组患儿的临床治疗总有效率(95.00%)高于单独用药组(78.33%),差异有统计学意义(P<0.05)。联合用药组患儿的咳嗽、喘息、哮鸣音改善时间,体温降至正常范围时间及住院天数均明显短于单独用药组,差异均有统计学意义(P<0.05)。治疗后,两组患儿的超敏C反应蛋白水平均低于治疗前,且联合用药组患儿的超敏C反应蛋白水平低于单独用药组,差异有统计学意义(P<0.05)。联合用药组患儿的不良反应发生率(3.33%)低于单独用药组(18.33%),差异有统计学意义(P<0.05)。结论孟鲁司特钠对喘息性支气管炎的治疗有较好的辅助作用,能有效提高临床疗效,患儿的各种症状改善均较快,不良反应发生率低,具有安全、可靠的特点。更多还原

【Abstract】 Objective To evaluate the effect of Montelukast assisted Azithromycin in the treatment of pediatric asthmatic bronchitis.Methods A total of 120 children with asthmatic bronchitis treated in our hospital from January 2016 to October 2017 were selected as subjects and divided into the single drug group and combination group according to random number table method,60 in each group.The single drug group were given Azithromycin alone and the combination group was treated with Montelukast Sodium assisted Azithromycin.The therapeutic effect,symptom relief time,the index of hypersensitive C-reactive protein(hs CRP) and the incidence of adverse reactions of two groups were compared.Results After treatment,the total effective rate of the children in the combination group(95.00%) was higher than that of the single drug group(78.33%),and the difference was statistically significant(P<0.05).The relief time of cough,wheezing,wheezing sound,the temperature dropped to the normal range and hospitalization days of the children in the combination group were significantly shorter than those in the single drug group,and the differences were statistically significant(P<0.05).After treatment,two groups of children with hypersensitive C-reactive protein levels were lower than before treatment,and combination group with hypersensitive C-reactive protein levels were lower than that in the single drug groups,the differences were statistically significant(P<0.05).The incidence of adverse reactions of the children in the combination group(3.33%) was lower than that of the single drug group(18.33%),and the difference was statistically significant(P<0.05).Conclusion Montelukast Sodium is a good adjuvant for the treatment of asthmatic bronchitis,it can improve the clinical efficacy.The improvement of various symptoms is rapid,and the incidence of adverse reactions low,with safety and reliability.更多还原